Luminex (LMNX) Receiving Somewhat Favorable Press Coverage, Report Shows
News headlines about Luminex (NASDAQ:LMNX) have been trending somewhat positive on Saturday, Alpha One reports. The research group, a division of Accern, rates the sentiment of media coverage by monitoring more than 20 million news and blog sources. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Luminex earned a daily sentiment score of 0.22 on Alpha One’s scale. Alpha One also gave news stories about the medical instruments supplier an impact score of 88 out of 100, indicating that recent media coverage is very likely to have an impact on the company’s share price in the next few days.
A number of research analysts recently issued reports on LMNX shares. TheStreet lowered Luminex from a “b-” rating to a “c+” rating in a report on Wednesday, March 8th. Zacks Investment Research lowered Luminex from a “hold” rating to a “sell” rating in a report on Monday, April 17th. Jefferies Group LLC reaffirmed a “hold” rating and set a $20.00 target price on shares of Luminex in a report on Tuesday, February 14th. William Blair reaffirmed a “market perform” rating on shares of Luminex in a report on Tuesday, February 7th. Finally, Deutsche Bank AG reaffirmed a “sell” rating and set a $18.00 target price on shares of Luminex in a report on Wednesday, January 18th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $21.83.
Luminex (NASDAQ:LMNX) traded down 1.09% during trading on Friday, hitting $20.83. The company had a trading volume of 210,582 shares. The firm has a 50-day moving average of $18.93 and a 200 day moving average of $19.50. The company has a market capitalization of $914.98 million, a price-to-earnings ratio of 64.69 and a beta of 0.59. Luminex has a 12-month low of $17.64 and a 12-month high of $23.75.
Luminex (NASDAQ:LMNX) last released its quarterly earnings results on Monday, May 1st. The medical instruments supplier reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.16 by $0.12. The business had revenue of $77.80 million during the quarter, compared to the consensus estimate of $74.25 million. Luminex had a return on equity of 5.53% and a net margin of 5.10%. The company’s quarterly revenue was up 23.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.29 EPS. On average, equities research analysts forecast that Luminex will post $0.52 earnings per share for the current year.
The firm also recently announced a special dividend, which was paid on Friday, April 14th. Stockholders of record on Friday, March 24th were paid a $0.06 dividend. The ex-dividend date of this dividend was Wednesday, March 22nd.
WARNING: “Luminex (LMNX) Receiving Somewhat Favorable Press Coverage, Report Shows” was originally reported by Markets Daily and is the property of of Markets Daily. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.themarketsdaily.com/2017/05/13/luminex-lmnx-given-daily-news-sentiment-rating-of-0-22-updated.html.
Luminex Company Profile
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.
Receive News & Ratings for Luminex Co. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Co. and related companies with MarketBeat.com's FREE daily email newsletter.